{
  "session_id": "bcec84a3-1b86-4c8c-9ee7-21323e95d4a3",
  "timestamp": "2025-10-06T00:28:55.042639Z",
  "dataset_format": "MIT_PDDL_BlocksWorld_RLHF",
  "reference": "https://github.com/CassieHuang22/llm-as-pddl-formalizer",
  "original_prompt": "give me the step by step reasoning instruction to analyze the company's financial statements and annual shareholders meeting. figure out what are the key financial and business metrics investors tract for that company.  then give me a one page highlight which investors must know followed by 10 questions an investor should ask the CEO.",
  "model_output": "## 1\ufe0f\u20e3 Step\u2011by\u2011Step Reasoning Guide to Analyze a Company\u2019s Financial Statements & Annual Shareholders\u2019 Meeting  \n\n| Phase | Action | Why it matters | Tips / Tools |\n|-------|--------|----------------|--------------|\n| **A. Preparation** | 1. **Collect the source documents** \u2013 10\u2011K/20\u2011F, annual report, proxy statement (DEF 14A), earnings press release, slide deck from the shareholders\u2019 meeting, and any supplemental investor presentations. | You need the complete, audited data set to avoid gaps. | Use the SEC\u2019s EDGAR database (or the company\u2019s investor\u2011relations site). |\n| | 2. **Set the context** \u2013 Identify the industry, competitive landscape, and macro\u2011economic trends for the reporting period. | Metrics are meaningful only relative to peers and market conditions. | Look at industry reports (e.g., IBISWorld, Gartner, S&P Capital IQ). |\n| **B. Financial\u2011Statement Deep\u2011Dive** | 3. **Read the Management Discussion & Analysis (MD&A)** first. Highlight key drivers, risks, and forward\u2011looking statements. | MD&A explains the \u201cstory\u201d behind the numbers. | Flag any changes in accounting policy or one\u2011off items. |\n| | 4. **Re\u2011create the three core statements** (Income Statement, Balance Sheet, Cash\u2011Flow Statement) in a spreadsheet. | Enables you to recompute ratios, adjust for non\u2011recurring items, and spot inconsistencies. | Use the \u201cre\u2011statement\u201d technique: start with net income, add back depreciation, adjust for working\u2011capital changes, etc. |\n| | 5. **Perform horizontal (year\u2011over\u2011year) and vertical (percentage\u2011of\u2011sales) analysis** for each statement. | Shows growth trends and cost structure. | Horizontal: %\u0394 = (Current \u2013 Prior) / Prior. Vertical: % of revenue for income, % of total assets for balance sheet. |\n| | 6. **Calculate the core financial ratios** (see Section\u202f2). Put them in a table and compare to: <br>\u2022 Prior years (trend) <br>\u2022 Industry averages <br>\u2022 Company\u2019s own guidance. | Ratios condense complex data into actionable signals. | Use Bloomberg, FactSet, or free sites like Macrotrends for peer benchmarks. |\n| | 7. **Audit the footnotes** \u2013 Look for off\u2011balance\u2011sheet items, debt covenants, stock\u2011based compensation, related\u2011party transactions, and contingent liabilities. | Footnotes often contain the \u201creal\u201d risk exposures. | Highlight any changes in lease accounting (ASC\u202f842/IFRS\u202f16) or goodwill impairments. |\n| **C. Shareholders\u2019 Meeting Review** | 8. **Watch the meeting (or read the transcript)** and note: <br>\u2022 CEO\u2019s strategic priorities <br>\u2022 Board\u2019s questions & answers <br>\u2022 Shareholder proposals and voting outcomes. | Direct insight into management\u2019s confidence and board\u2011shareholder alignment. | Use a highlighter to tag any \u201cforward\u2011looking\u201d language (e.g., \u201cwe expect \u2026 in FY24\u201d). |\n| | 9. **Cross\u2011reference the meeting commentary with the MD&A** \u2013 Do the numbers support the narrative? | Consistency builds credibility; discrepancies may signal risk. | Create a two\u2011column table: \u201cManagement claim\u201d vs. \u201cFinancial evidence\u201d. |\n| | 10. **Identify any governance red flags** \u2013 e.g., high CEO turnover, related\u2011party voting, activist shareholder pressure. | Governance quality is a material factor for many investors. | Check proxy statement for director independence, compensation tables, and shareholder proposals. |\n| **D. Synthesis** | 11. **Summarize the key take\u2011aways** in a one\u2011page \u201cInvestor Highlight\u201d (see Section\u202f3). | Provides a quick\u2011reference for decision\u2011makers. | Keep it visual \u2013 use bullet points, mini\u2011charts, and a concise risk\u2011reward matrix. |\n| | 12. **Prepare a list of probing questions for the CEO** (see Section\u202f4). | Ensures you get the information you need in the next earnings call or meeting. | Prioritize questions that address gaps you uncovered in steps\u202f5\u20119. |\n\n---\n\n## 2\ufe0f\u20e3 Core Financial & Business Metrics Investors Track  \n\n| Category | Metric | Formula / What to Look For | Typical \u201cHealthy\u201d Benchmark (varies by sector) |\n|----------|--------|----------------------------|-----------------------------------------------|\n| **Profitability** | **Revenue Growth YoY** | (Current\u202fRev \u2013 Prior\u202fRev) / Prior\u202fRev | 5\u201115\u202f% for mature firms; >20\u202f% for high\u2011growth tech |\n| | **Gross Margin** | Gross Profit / Revenue | >40\u202f% for software, >20\u202f% for manufacturing |\n| | **Operating Margin (EBIT / Rev)** | EBIT / Revenue | >15\u202f% for stable cash\u2011generators |\n| | **Net Margin** | Net Income / Revenue | >10\u202f% for mature firms |\n| | **Return on Equity (ROE)** | Net Income / Shareholder Equity | 12\u201120\u202f% |\n| | **Return on Invested Capital (ROIC)** | NOPAT / (Debt\u202f+\u202fEquity\u202f\u2013\u202fCash) | >10\u202f% |\n| **Liquidity & Working Capital** | **Current Ratio** | Current Assets / Current Liabilities | 1.2\u20112.0 |\n| | **Quick Ratio** | (Cash\u202f+\u202fMarketable\u202fSec\u202f+\u202fReceivables) / Current Liabilities | >1.0 |\n| | **Days Sales Outstanding (DSO)** | (Accounts Receivable / Revenue) \u00d7 365 | Lower is better; <45\u202fdays typical |\n| **Leverage & Solvency** | **Debt\u2011to\u2011Equity (D/E)** | Total Debt / Shareholder Equity | <1.0 for most non\u2011financials |\n| | **Net Debt\u2011to\u2011EBITDA** | (Total Debt \u2013 Cash) / EBITDA | <3\u20114x |\n| | **Interest Coverage** | EBIT / Interest Expense | >3\u20114x |\n| **Cash Flow** | **Operating Cash Flow (OCF) / Revenue** | OCF / Revenue | >15\u201120\u202f% |\n| | **Free Cash Flow (FCF) Yield** | FCF / Market Capitalization | >5\u202f% |\n| | **Capital Expenditure Ratio** | CapEx / OCF | <0.5 (excessive capex may strain cash) |\n| **Growth & Efficiency** | **Revenue per Employee** | Revenue / # Employees | Benchmark by industry |\n| | **EBITDA Margin** | EBITDA / Revenue | 15\u201130\u202f% for many mid\u2011size firms |\n| **Valuation** | **Price\u2011to\u2011Earnings (P/E)** | Share Price / EPS | 15\u201125\u00d7 for stable companies |\n| | **EV/EBITDA** | Enterprise Value / EBITDA | 8\u201112\u00d7 |\n| | **Price\u2011to\u2011Book (P/B)** | Share Price / Book Value per Share | 1\u20113\u00d7 |\n| **Shareholder\u2011Centric** | **Dividend Yield** | Annual Dividend / Share Price | 2\u20114\u202f% for mature dividend payers |\n| | **Payout Ratio** | Dividends / Net Income | 30\u201160\u202f% |\n| | **Share Repurchase Activity** | % of Shares Repurchased YoY | Indicates confidence in undervaluation |\n| **Strategic / Business** | **Customer Acquisition Cost (CAC)** | Sales & Marketing / New Customers | Lower CAC vs. LTV is a win |\n| | **Lifetime Value (LTV)** | Gross Margin \u00d7 Avg. Customer Lifespan | LTV\u202f>\u202f3\u202f\u00d7\u202fCAC is a rule\u2011of\u2011thumb |\n| | **Churn Rate** (for subscription models) | Lost Customers / Total Customers | <5\u202f% annual churn is strong |\n| | **Geographic / Segment Revenue Mix** | % Rev from each region/segment | Diversification reduces concentration risk |\n| | **R&D Intensity** | R&D Expense / Revenue | 5\u201115\u202f% for tech/biopharma; lower for utilities |\n| | **ESG Scores** (if material) | Third\u2011party ESG rating | Growing importance for institutional investors |\n\n---\n\n## 3\ufe0f\u20e3 One\u2011Page Investor Highlight (Template)\n\n> **[Company Name] \u2013 FY\u202f2024 Investor Snapshot**  \n> *(All figures are FY\u2011ended 31\u202fDec\u202f2024 unless noted)*  \n\n| **Financial Overview** | 2024 | 2023 | YoY % | Comment |\n|------------------------|------|------|------|---------|\n| Revenue | $X.XX\u202fbn | $X.XX\u202fbn | +Y\u202f% | Driven by **[key driver]** (e.g., new product line, geographic expansion). |\n| Gross Margin | Z\u202f% | Z\u202f% | \u00b1 | Stable despite **[cost pressure]**. |\n| Operating Income (EBIT) | $X\u202fm | $X\u202fm | +Y\u202f% | Margin improvement from **[efficiency initiative]**. |\n| Net Income | $X\u202fm | $X\u202fm | +Y\u202f% | Includes **[one\u2011off item]** (e.g., tax benefit). |\n| EPS (Diluted) | $X.XX | $X.XX | +Y\u202f% | |\n| Free Cash Flow | $X\u202fm | $X\u202fm | +Y\u202f% | Supports **[share repurchase/dividend]**. |\n| Net Debt / EBITDA | X.X\u00d7 | X.X\u00d7 | \u2013 | Debt reduction via **[cash\u2011flow usage]**. |\n| Dividend Yield | X\u202f% | X\u202f% | \u2013 | Consistent payout; **[payout ratio]** at X\u202f%. |\n\n**Key Business Metrics**  \n- **Customer Base:** 1.2\u202fM active users (+12\u202f% YoY).  \n- **Churn:** 4.3\u202f% (industry avg 6\u202f%).  \n- **R&D Intensity:** 9\u202f% of revenue \u2013 focus on **[next\u2011gen product]**.  \n- **Geographic Mix:** 55\u202f% U.S., 30\u202f% Europe, 15\u202f% Asia\u2011Pac (no single market >30\u202f%).  \n\n**Strategic Highlights from 2024 Shareholders\u2019 Meeting**  \n- **CEO Outlook:** Target **15\u202f% revenue CAGR** through 2027 via **[new platform]** and **[M&A pipeline]**.  \n- **Board Approval:** $X\u202fbn share\u2011repurchase program; **[increase]** in dividend to $X per share.  \n- **Governance:** Appointment of two independent directors; enhanced ESG reporting.  \n\n**Risks & Mitigants**  \n| Risk | Likelihood | Impact | Mitigation |\n|------|------------|--------|------------|\n| **Supply\u2011chain constraints** (e.g., semiconductor shortage) | Medium | Revenue volatility | Dual\u2011sourcing contracts, inventory buffer. |\n| **Regulatory change in EU data\u2011privacy** | Low | Potential compliance cost | Dedicated compliance team; early adoption of GDPR\u2011plus. |\n| **Competitive pressure from **[rival]** | High | Margin erosion | Accelerated product roadmap; strategic partnerships. |\n| **Interest\u2011rate rise** | Medium | Higher debt\u2011service cost | Net\u2011debt reduction; floating\u2011rate hedges. |\n\n**Valuation Snapshot**  \n- **Current P/E:** 18\u00d7 (vs. industry avg 21\u00d7)  \n- **EV/EBITDA:** 9.5\u00d7 (vs. peer median 10.8\u00d7)  \n- **FCF Yield:** 6.2\u202f% (above 5\u202f% threshold)  \n\n**Bottom\u2011Line Takeaway**  \nThe company delivered solid top\u2011line growth, improved cash generation, and a disciplined capital\u2011allocation plan. With a diversified revenue base, low churn, and a clear strategic roadmap, the upside potential appears **[X]** while key risks are **[moderately]** managed.  \n\n---\n\n## 4\ufe0f\u20e3 Ten Questions an Investor Should Ask the CEO (or CFO)  \n\n1. **Growth Drivers:** *\u201cWhat are the top three revenue\u2011growth initiatives for the next 12\u201118 months, and how do you quantify their expected contribution?\u201d*  \n2. **Margin Sustainability:** *\u201cGiven the recent cost pressures (e.g., raw\u2011material, labor), what specific actions are you taking to protect or improve operating margins?\u201d*  \n3. **Capital Allocation:** *\u201cCan you walk us through the rationale behind the current share\u2011repurchase program versus potential reinvestment in R&D or acquisitions?\u201d*  \n4. **M&A Strategy:** *\u201cDo you have a defined M&A pipeline? If so, what criteria (size, geography, technology) guide target selection?\u201d*  \n5. **Customer Retention:** *\u201cWhat is your churn rate trend, and what initiatives are in place to improve customer lifetime value?\u201d*  \n6. **Competitive Landscape:** *\u201cHow do you assess the threat from emerging competitors, especially those leveraging AI/ML, and what differentiates your offering?\u201d*  \n7. **Regulatory & ESG Risks:** *\u201cAre there any upcoming regulatory changes (domestic or international) that could materially affect the business, and how are you preparing for them?\u201d*  \n8. **Balance\u2011Sheet Management:** *\u201cWith the current debt level, what is your plan for debt reduction or refinancing, especially in a rising\u2011rate environment?\u201d*  \n9. **Guidance & Forecasting:** *\u201cYour FY\u20112025 guidance assumes X% revenue growth\u2014what are the key assumptions behind that number, and what would cause a material deviation?\u201d*  \n10. **Talent & Culture:** *\u201cGiven the importance of innovation, how are you attracting and retaining top talent, and what cultural initiatives support long\u2011term performance?\u201d*  \n\n---  \n\n**How to Use This Material**  \n- **Before the call:** Run the ratio analysis (Section\u202f2) and fill in the one\u2011page highlight (Section\u202f3) with the latest numbers.  \n- **During the meeting:** Reference the highlight to keep the discussion focused; ask the 10 questions (or a subset) to probe gaps.  \n- **After the call:** Update your financial model with any new guidance, and re\u2011run the valuation metrics to see the impact on your investment thesis.  \n\nGood luck with your analysis! \ud83d\ude80",
  "pddl_structure": {
    "domain_definition": null,
    "problem_definition": null,
    "plan_sequence": "One\u2011Page Investor Highlight (Template)\n\n> **[Company Name] \u2013 FY\u202f2024 Investor Snapshot**  \n> *(All figures are FY\u2011ended 31\u202fDec\u202f2024 unless noted)*  \n\n| **Financial Overview** | 2024 | 2023 | YoY % | Comment |\n|",
    "validation": {
      "is_valid_structure": false,
      "has_domain": false,
      "has_problem": false,
      "has_actions": false,
      "has_predicates": false,
      "errors": []
    }
  },
  "model_metadata": {
    "model": "accounts/colin-fbf68a/models/pddl-gpt-oss-model",
    "temperature": 0.2,
    "max_tokens": 10000,
    "prompt_tokens": 144,
    "completion_tokens": 3249,
    "total_tokens": 3393
  },
  "human_feedback": [
    {
      "step_id": "step-1",
      "step_number": 1,
      "step_content": "## 1. Step\u2011by\u2011Step Reasoning Guide to Analyze a Company\u2019s Financial Statements & Annual Shareholders\u2019 Meeting\n\n| Phase | Action | Why it matters | Tips / Tools |\n|-------|--------|----------------|--------------|\n| **A. Preparation** | 1. **Collect the source documents** \u2013 10\u2011K/20\u2011F, annual report, proxy statement (DEF 14A), earnings press release, slide deck from the shareholders\u2019 meeting, and any supplemental investor presentations. | You need the complete, audited data set to avoid gaps. | Use the SEC\u2019s EDGAR database (or the company\u2019s investor\u2011relations site). |\n| | 2. **Set the context** \u2013 Identify the industry, competitive landscape, and macro\u2011economic trends for the reporting period. | Metrics are meaningful only relative to peers and market conditions. | Look at industry reports (e.g., IBISWorld, Gartner, S&P Capital IQ). |\n| **B. Financial\u2011Statement Deep\u2011Dive** | 3. **Read the Management Discussion & Analysis (MD&A)** first. Highlight key drivers, risks, and forward\u2011looking statements. | MD&A explains the \u201cstory\u201d behind the numbers. | Flag any changes in accounting policy or one\u2011off items. |\n| | 4. **Re\u2011create the three core statements** (Income Statement, Balance Sheet, Cash\u2011Flow Statement) in a spreadsheet. | Enables you to recompute ratios, adjust for non\u2011recurring items, and spot inconsistencies. | Use the \u201cre\u2011statement\u201d technique: start with net income, add back depreciation, adjust for working\u2011capital changes, etc. |\n| | 5. **Perform horizontal (year\u2011over\u2011year) and vertical (percentage\u2011of\u2011sales) analysis** for each statement. | Shows growth trends and cost structure. | Horizontal: %\u0394 = (Current \u2013 Prior) / Prior. Vertical: % of revenue for income, % of total assets for balance sheet. |\n| | 6. **Calculate the core financial ratios** (see Section\u202f2). Put them in a table and compare to: <br>\u2022 Prior years (trend) <br>\u2022 Industry averages <br>\u2022 Company\u2019s own guidance. | Ratios condense complex data into actionable signals. | Use Bloomberg, FactSet, or free sites like Macrotrends for peer benchmarks. |\n| | 7. **Audit the footnotes** \u2013 Look for off\u2011balance\u2011sheet items, debt covenants, stock\u2011based compensation, related\u2011party transactions, and contingent liabilities. | Footnotes often contain the \u201creal\u201d risk exposures. | Highlight any changes in lease accounting (ASC\u202f842/IFRS\u202f16) or goodwill impairments. |\n| **C. Shareholders\u2019 Meeting Review** | 8. **Watch the meeting (or read the transcript)** and note: <br>\u2022 CEO\u2019s strategic priorities <br>\u2022 Board\u2019s questions & answers <br>\u2022 Shareholder proposals and voting outcomes. | Direct insight into management\u2019s confidence and board\u2011shareholder alignment. | Use a highlighter to tag any \u201cforward\u2011looking\u201d language (e.g., \u201cwe expect \u2026 in FY24\u201d). |\n| | 9. **Cross\u2011reference the meeting commentary with the MD&A** \u2013 Do the numbers support the narrative? | Consistency builds credibility; discrepancies may signal risk. | Create a two\u2011column table: \u201cManagement claim\u201d vs. \u201cFinancial evidence\u201d. |\n| | 10. **Identify any governance red flags** \u2013 e.g., high CEO turnover, related\u2011party voting, activist shareholder pressure. | Governance quality is a material factor for many investors. | Check proxy statement for director independence, compensation tables, and shareholder proposals. |\n| **D. Synthesis** | 11. **Summarize the key take\u2011aways** in a one\u2011page \u201cInvestor Highlight\u201d (see Section\u202f3). | Provides a quick\u2011reference for decision\u2011makers. | Keep it visual \u2013 use bullet points, mini\u2011charts, and a concise risk\u2011reward matrix. |\n| | 12. **Prepare a list of probing questions for the CEO** (see Section\u202f4). | Ensures you get the information you need in the next earnings call or meeting. | Prioritize questions that address gaps you uncovered in steps\u202f5\u20119. |\n\n---",
      "rating": "positive",
      "reason": null,
      "feedback_quality": "basic"
    },
    {
      "step_id": "step-2",
      "step_number": 2,
      "step_content": "## 2. Core Financial & Business Metrics Investors Track\n\n| Category | Metric | Formula / What to Look For | Typical \u201cHealthy\u201d Benchmark (varies by sector) |\n|----------|--------|----------------------------|-----------------------------------------------|\n| **Profitability** | **Revenue Growth YoY** | (Current\u202fRev \u2013 Prior\u202fRev) / Prior\u202fRev | 5\u201115\u202f% for mature firms; >20\u202f% for high\u2011growth tech |\n| | **Gross Margin** | Gross Profit / Revenue | >40\u202f% for software, >20\u202f% for manufacturing |\n| | **Operating Margin (EBIT / Rev)** | EBIT / Revenue | >15\u202f% for stable cash\u2011generators |\n| | **Net Margin** | Net Income / Revenue | >10\u202f% for mature firms |\n| | **Return on Equity (ROE)** | Net Income / Shareholder Equity | 12\u201120\u202f% |\n| | **Return on Invested Capital (ROIC)** | NOPAT / (Debt\u202f+\u202fEquity\u202f\u2013\u202fCash) | >10\u202f% |\n| **Liquidity & Working Capital** | **Current Ratio** | Current Assets / Current Liabilities | 1.2\u20112.0 |\n| | **Quick Ratio** | (Cash\u202f+\u202fMarketable\u202fSec\u202f+\u202fReceivables) / Current Liabilities | >1.0 |\n| | **Days Sales Outstanding (DSO)** | (Accounts Receivable / Revenue) \u00d7 365 | Lower is better; <45\u202fdays typical |\n| **Leverage & Solvency** | **Debt\u2011to\u2011Equity (D/E)** | Total Debt / Shareholder Equity | <1.0 for most non\u2011financials |\n| | **Net Debt\u2011to\u2011EBITDA** | (Total Debt \u2013 Cash) / EBITDA | <3\u20114x |\n| | **Interest Coverage** | EBIT / Interest Expense | >3\u20114x |\n| **Cash Flow** | **Operating Cash Flow (OCF) / Revenue** | OCF / Revenue | >15\u201120\u202f% |\n| | **Free Cash Flow (FCF) Yield** | FCF / Market Capitalization | >5\u202f% |\n| | **Capital Expenditure Ratio** | CapEx / OCF | <0.5 (excessive capex may strain cash) |\n| **Growth & Efficiency** | **Revenue per Employee** | Revenue / # Employees | Benchmark by industry |\n| | **EBITDA Margin** | EBITDA / Revenue | 15\u201130\u202f% for many mid\u2011size firms |\n| **Valuation** | **Price\u2011to\u2011Earnings (P/E)** | Share Price / EPS | 15\u201125\u00d7 for stable companies |\n| | **EV/EBITDA** | Enterprise Value / EBITDA | 8\u201112\u00d7 |\n| | **Price\u2011to\u2011Book (P/B)** | Share Price / Book Value per Share | 1\u20113\u00d7 |\n| **Shareholder\u2011Centric** | **Dividend Yield** | Annual Dividend / Share Price | 2\u20114\u202f% for mature dividend payers |\n| | **Payout Ratio** | Dividends / Net Income | 30\u201160\u202f% |\n| | **Share Repurchase Activity** | % of Shares Repurchased YoY | Indicates confidence in undervaluation |\n| **Strategic / Business** | **Customer Acquisition Cost (CAC)** | Sales & Marketing / New Customers | Lower CAC vs. LTV is a win |\n| | **Lifetime Value (LTV)** | Gross Margin \u00d7 Avg. Customer Lifespan | LTV\u202f>\u202f3\u202f\u00d7\u202fCAC is a rule\u2011of\u2011thumb |\n| | **Churn Rate** (for subscription models) | Lost Customers / Total Customers | <5\u202f% annual churn is strong |\n| | **Geographic / Segment Revenue Mix** | % Rev from each region/segment | Diversification reduces concentration risk |\n| | **R&D Intensity** | R&D Expense / Revenue | 5\u201115\u202f% for tech/biopharma; lower for utilities |\n| | **ESG Scores** (if material) | Third\u2011party ESG rating | Growing importance for institutional investors |\n\n---",
      "rating": "positive",
      "reason": null,
      "feedback_quality": "basic"
    },
    {
      "step_id": "step-3",
      "step_number": 3,
      "step_content": "## 3. One\u2011Page Investor Highlight (Template)\n\n> **[Company Name] \u2013 FY\u202f2024 Investor Snapshot**\n> *(All figures are FY\u2011ended 31\u202fDec\u202f2024 unless noted)*\n\n| **Financial Overview** | 2024 | 2023 | YoY % | Comment |\n|------------------------|------|------|------|---------|\n| Revenue | $X.XX\u202fbn | $X.XX\u202fbn | +Y\u202f% | Driven by **[key driver]** (e.g., new product line, geographic expansion). |\n| Gross Margin | Z\u202f% | Z\u202f% | \u00b1 | Stable despite **[cost pressure]**. |\n| Operating Income (EBIT) | $X\u202fm | $X\u202fm | +Y\u202f% | Margin improvement from **[efficiency initiative]**. |\n| Net Income | $X\u202fm | $X\u202fm | +Y\u202f% | Includes **[one\u2011off item]** (e.g., tax benefit). |\n| EPS (Diluted) | $X.XX | $X.XX | +Y\u202f% | |\n| Free Cash Flow | $X\u202fm | $X\u202fm | +Y\u202f% | Supports **[share repurchase/dividend]**. |\n| Net Debt / EBITDA | X.X\u00d7 | X.X\u00d7 | \u2013 | Debt reduction via **[cash\u2011flow usage]**. |\n| Dividend Yield | X\u202f% | X\u202f% | \u2013 | Consistent payout; **[payout ratio]** at X\u202f%. |\n\n**Key Business Metrics**\n- **Customer Base:** 1.2\u202fM active users (+12\u202f% YoY).\n- **Churn:** 4.3\u202f% (industry avg 6\u202f%).\n- **R&D Intensity:** 9\u202f% of revenue \u2013 focus on **[next\u2011gen product]**.\n- **Geographic Mix:** 55\u202f% U.S., 30\u202f% Europe, 15\u202f% Asia\u2011Pac (no single market >30\u202f%).\n\n**Strategic Highlights from 2024 Shareholders\u2019 Meeting**\n- **CEO Outlook:** Target **15\u202f% revenue CAGR** through 2027 via **[new platform]** and **[M&A pipeline]**.\n- **Board Approval:** $X\u202fbn share\u2011repurchase program; **[increase]** in dividend to $X per share.\n- **Governance:** Appointment of two independent directors; enhanced ESG reporting.\n\n**Risks & Mitigants**\n| Risk | Likelihood | Impact | Mitigation |\n|------|------------|--------|------------|\n| **Supply\u2011chain constraints** (e.g., semiconductor shortage) | Medium | Revenue volatility | Dual\u2011sourcing contracts, inventory buffer. |\n| **Regulatory change in EU data\u2011privacy** | Low | Potential compliance cost | Dedicated compliance team; early adoption of GDPR\u2011plus. |\n| **Competitive pressure from **[rival]** | High | Margin erosion | Accelerated product roadmap; strategic partnerships. |\n| **Interest\u2011rate rise** | Medium | Higher debt\u2011service cost | Net\u2011debt reduction; floating\u2011rate hedges. |\n\n**Valuation Snapshot**\n- **Current P/E:** 18\u00d7 (vs. industry avg 21\u00d7)\n- **EV/EBITDA:** 9.5\u00d7 (vs. peer median 10.8\u00d7)\n- **FCF Yield:** 6.2\u202f% (above 5\u202f% threshold)\n\n**Bottom\u2011Line Takeaway**\nThe company delivered solid top\u2011line growth, improved cash generation, and a disciplined capital\u2011allocation plan. With a diversified revenue base, low churn, and a clear strategic roadmap, the upside potential appears **[X]** while key risks are **[moderately]** managed.\n\n---",
      "rating": "positive",
      "reason": null,
      "feedback_quality": "basic"
    },
    {
      "step_id": "step-4",
      "step_number": 4,
      "step_content": "## 4. Ten Questions an Investor Should Ask the CEO (or CFO)\n\n1. **Growth Drivers:** *\u201cWhat are the top three revenue\u2011growth initiatives for the next 12\u201118 months, and how do you quantify their expected contribution?\u201d*\n2. **Margin Sustainability:** *\u201cGiven the recent cost pressures (e.g., raw\u2011material, labor), what specific actions are you taking to protect or improve operating margins?\u201d*\n3. **Capital Allocation:** *\u201cCan you walk us through the rationale behind the current share\u2011repurchase program versus potential reinvestment in R&D or acquisitions?\u201d*\n4. **M&A Strategy:** *\u201cDo you have a defined M&A pipeline? If so, what criteria (size, geography, technology) guide target selection?\u201d*\n5. **Customer Retention:** *\u201cWhat is your churn rate trend, and what initiatives are in place to improve customer lifetime value?\u201d*\n6. **Competitive Landscape:** *\u201cHow do you assess the threat from emerging competitors, especially those leveraging AI/ML, and what differentiates your offering?\u201d*\n7. **Regulatory & ESG Risks:** *\u201cAre there any upcoming regulatory changes (domestic or international) that could materially affect the business, and how are you preparing for them?\u201d*\n8. **Balance\u2011Sheet Management:** *\u201cWith the current debt level, what is your plan for debt reduction or refinancing, especially in a rising\u2011rate environment?\u201d*\n9. **Guidance & Forecasting:** *\u201cYour FY\u20112025 guidance assumes X% revenue growth\u2014what are the key assumptions behind that number, and what would cause a material deviation?\u201d*\n10. **Talent & Culture:** *\u201cGiven the importance of innovation, how are you attracting and retaining top talent, and what cultural initiatives support long\u2011term performance?\u201d*\n\n---\n\n**How to Use This Material**\n- **Before the call:** Run the ratio analysis (Section\u202f2) and fill in the one\u2011page highlight (Section\u202f3) with the latest numbers.\n- **During the meeting:** Reference the highlight to keep the discussion focused; ask the 10 questions (or a subset) to probe gaps.\n- **After the call:** Update your financial model with any new guidance, and re\u2011run the valuation metrics to see the impact on your investment thesis.\n\nGood luck with your analysis! \ud83d\ude80",
      "rating": "positive",
      "reason": null,
      "feedback_quality": "basic"
    }
  ],
  "aggregated_metrics": {
    "total_steps": 4,
    "positive_ratings": 4,
    "negative_ratings": 0,
    "overall_score": 1.0,
    "pddl_validity_score": 0.0
  },
  "training_metadata": {
    "pipeline_type": "llm-as-formalizer",
    "evaluation_method": "human_feedback",
    "domain_type": "general_planning",
    "can_use_for_training": false
  }
}